Emulate focuses on commercializing Organs-on-Chips as an automated, human bio-emulation platform that achieves a new standard for mimicking human physiology so that responses to medicines, chemicals, and diseases can be accurately predicted.
Missing: Emulate's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
ESPs containing Emulate
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
These companies use patient-derived cells and tissue samples to create structures that mimic human physiology. These solutions come in two categories. Some vendors develop organoids, which are miniaturized and simplified versions of organs and tissue structures. Other vendors insert human cells into microfluidic assays in order to emulate human physiology.
Missing: Emulate's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Emulate
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Emulate in 2 CB Insights research briefs, most recently on Dec 16, 2020.
Expert Collections containing Emulate
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Emulate is included in 5 Expert Collections, including Clinical Trials Tech.
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
Digital Health 150
2019's cohort of the most promising digital health startups transforming the healthcare industry
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Emulate has filed 94 patents.
Digestive system, Transcription factors, Clusters of differentiation, Muscarinic antagonists, Biotechnology
Digestive system, Transcription factors, Clusters of differentiation, Muscarinic antagonists, Biotechnology
Latest Emulate News
Dec 16, 2022
News provided by Share this article Share this article WASHINGTON, Dec. 16, 2022 /PRNewswire/ -- In an opinion article published today in Frontiers Medical Technology, section on Pharmaceutical Innovation link here , Center for Contemporary Sciences (CCS) lists a dozen reasons why Organ-Chips are better than animal experimentation at modeling human disease and for drug development. In this article, CCS Chief Science Officer Dr. Zaher Nahle conducts an analysis of a landmark study published on December 6, 2022, in Nature Communications Medicine by Emulate, Inc. The existing drug development paradigm, established by statute in 1938 under the Federal Food, Drug, and Cosmetics Act (FFDCA), requires animal tests to be conducted to assess safety and efficacy in all new drug applications submitted for regulatory approvals, even though 90—95% of drugs that pass animal testing fail when tried in humans. As such, a growing number of stakeholders worldwide are demanding human relevancy across scientific research, including preclinical studies and drug development. The CCS opinion piece, titled "A Proof-of-Concept Study Poised to Remodel the Drug Development Process Liver-Chip Solutions for Lead Optimization and Predictive Toxicology" articulates some of the current concepts associated with the topic of human relevancy in preclinical research. Importantly, it sheds the light on the solutions offered by Organ-Chips, especially in predicting liver toxicity. Liver toxicity is the leading cause of termination of clinical trials due to toxicity. In turn, unmanaged toxicity is a major impediment in drug development, accounting for around 30% of clinical trial failures. The opinion article also comprehensively evaluates a study by Emulate, showing the superiority of Liver-Chips in predicting drug liver toxicity in humans, as compared to existing standard methods like animal testing. Specifically, the Emulate human Liver-Chips correctly identified 87% of drugs that caused serious liver toxicity and deaths in patients despite passing through animal testing. Moreover, the opinion article assesses the economic argument presented therein showing that $billions in productivity gains can be acquired by incorporating the technology into the drug development process at the preclinical stages. This is an important development in pharmaceutical medicine. Some of the areas specifically addressed in the CCS article include the important focus on liver toxicity, the marked sensitivity demonstrated in predicting the toxicity of drugs by the Liver-Chips, the superior capability of the Liver-Chips to not falsely label safe drug candidates as toxic, the convincing economic argument for using Liver-Chips, the rigorous quality control performed in the Emulate study, as well as the existing limitations of the technology at this point. "The Emulate study is one of the most critical developments in the field of Organ-on-a-Chip technology," said Zaher Nahle, PhD, MPA, Chief Science Officer at the Center for Contemporary Sciences. "It shows the primacy and utility of the technology in predictive toxicology. It also demonstrates the immediate readiness of such technology to transform critical phases of the drug development process, in particular lead optimization and preclinical assessment, making the entire process safer, cheaper, faster, and more effective. " "We will soon be embarking into a new era in medicine and medical research," says CCS CEO and Co-Founder Aysha Akhtar, MD, MPH. "Experimenting on animals, whose biology are vastly different from humans, will one day be a thing of the past and that is a good thing for human health and animal protection. Advanced testing methods based on human biology will revolutionize the way we approach medicine and health and lead to individualized medicine." For additional background and testimonials on the Emulate study, including Dr. Nahle's, see here. CCS continues to support work that enact policies and improved science to promote healthcare innovation and human-relevant testing. About Center for Contemporary Sciences Center for Contemporary Sciences (CCS) is pioneering a paradigm shift towards innovative, evidence-based research methods that are based on human biology. We champion technologies that are better for humans and that replace animal testing. SOURCE Center for Contemporary Sciences ×
Emulate Frequently Asked Questions (FAQ)
When was Emulate founded?
Emulate was founded in 2014.
Where is Emulate's headquarters?
Emulate's headquarters is located at 27 Drydock Avenue, Boston.
What is Emulate's latest funding round?
Emulate's latest funding round is Series E.
How much did Emulate raise?
Emulate raised a total of $227.17M.
Who are the investors of Emulate?
Investors of Emulate include Northpond Ventures, Perceptive Advisors, +ND Capital, Founders Fund, Blue Ivy Ventures and 14 more.
Who are Emulate's competitors?
Competitors of Emulate include InSphero, Quris AI, Kiyatec, Xellar Biosystems, FidoCure, Xilis, Aracari Biosciences, Finnadvance, Pear Bio, SUN Bioscience and 16 more.
Compare Emulate to Competitors
MIMETAS develops organ-on-a-chip technology for testing of new medicines. Its microfluidic technology enables testing of drug compounds in high-throughput on miniaturized organ models. These models have better predictivity compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlate platform supports 3D cell culture under continuous perfusion, membrane-free co-culture and boundary- and gradient formation. MIMETAS develops and validates customised disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection.
CN Bio provides micro-physiological systems that enable researchers to study drug metabolism, toxicology and specific disease models on single- and multi-organ systems. Providing efficiencies for pre-clinical drug testing with predictive human tissue-based data, the company’s technologies are able to replicate the micro-environments, cell-cell interactions and biological processes that occur in vivo, to bridge the gap between traditional cell culture assays and human studies, improving drug discovery while reducing research and development costs.
TissUse is a growth company that has developed a Multi-Organ-Chip platform that provides preclinical insight on the systemic level using human tissue. This enabling technology platform consists of a miniaturized construct that simulates the activity of multiple human organs in their true physiological context. TissUse's Multi-Organ-Chips provide an approach to predict, for example, toxicity, ADME profiles, and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.
Hubrecht Organoid Technology (HUB) is a biotechnology company that provides development, preclinical patient stratification, predictive biomarker discovery, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics applications. It is based in Utrecht, Nederland.
Quris AI is a pharmaceutical artificial intelligence firm that develops a clinical prediction AI platform that helps predict which drug candidates will safely work in humans, assisting in ensuring the safety and efficacy of new drugs and the repurposing and personalization of existing drugs. Its Bio-AI Clinical Prediction Platform generates proprietary data and uses machine learning to predict clinical safety and efficacy. The company was founded in 2019 and is based in Tel- Aviv Israel.
AxoSim facilitates preclinical prediction of neurological safety and efficacy early in the drug development pipeline. Employing microengineering techniques and biomaterials, the company has developed a 3D cell-based model which mimics living tissue in both form and function. By providing an alternative to exploratory animal testing, pharmaceutical companies will have access to high content data faster and earlier than currently possible.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.